vorolanib

all catalysts(0)

nothing on the calendar yet

News(5)

• STAT+: Pharmalittle: We’re reading about a setback for Eyepoint, a win for Amylyx, and more
  Eyepoint disclosed that a Phase 3 trial of its experimental treatment for a common cause of age-related blindness fell short of its primary goal
  stat · 2d ago
• STAT+: Eyepoint study results for vision treatment disappoint, but company still sees promise
  Eyepoint said patients given its experimental treatment for wet AMD failed to maintain vision with less frequent injections compared to a standard treatment.
  stat · 3d ago
• EyePoint plummets on pivotal data for main drug
  Though its drug missed the key goal of a wet AMD study, EyePoint — as well as analysts — see a path toward approval. Investors may be harder to win over, however.
  biopharma_dive · 3d ago
• EyePoint’s Phase 3 fail sends stock spiraling amid next-gen AMD race
  EyePoint’s quest to reduce treatment burden for patients with age-related macular degeneration has hit a bump in the road, with a clinical miss driving the biotech’s stock down by 70%.
  biospace · 3d ago
• Chutes & Ladders—Cue lines up new CMO and research head
  Cue Biopharma is tapping in a new chief medical officer and head of R&D in Dominic Borie, M.D., Ph.D., a physician-scientist with over two decades of industry experience.
  fiercebiotech · 1mo ago